Fujifilm Diosynth Biotechnologies

Fujifilm Diosynth Biotechnologies Manufactures New Licensed Biopharmaceutical

Jetrea is FDA-approved for treatment of symptomatic vitreomacular adhesion.

Fujifilm Diosynth Biotechnologies has added another licensed product to its list of commercial biopharmaceutical products, following the announcement that ThromboGenics' has received FDA approval for the launch of JETREA® (ocriplasmin) in the USA for the treatment of Symptomatic Vitreomacular Adhesion (VMA). 

No votes yet
Syndicate content